<DOC>
	<DOCNO>NCT01078805</DOCNO>
	<brief_summary>The purpose study evaluate long-term effectiveness , safety , tolerability FORTEO large , diverse `` real world '' population study clinical trial</brief_summary>
	<brief_title>Study FORTEO Use Subjects Community Setting</brief_title>
	<detailed_description>Subjects follow course FORTEO therapy 24 month additional 24 month FORTEO treatment stop . Subjects may participate study 48 month . All aspect patient care , include diagnostic therapeutic intervention , choose conduct discretion participate study physician accord clinical judgment local standard medical care .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Men woman judge study physician suitable FORTEO therapy . The FORTEO product label specifies individual diagnose osteoporosis consider high risk fracture Subjects increase baseline risk osteosarcoma . These include Paget 's disease bone , pediatric population young adult patient open epiphysis , prior external beam implant radiation therapy involve skeleton Subjects administer FORTEO PTH therapy two week directly study entry Subjects complete course FORTEO PTH therapy least 18 month duration study entry</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>